| Recruiting | Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors NCT06819215 | Zhejiang Yangli Pharmaceutical Technology Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in NCT05849480 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Recruiting | Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG) NCT06101277 | University of California, Davis | N/A |
| Recruiting | Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection NCT05517811 | University of Colorado, Denver | — |
| Completed | Intestinal Microbiome, Oral Microbiome, and Whole Blood Transcriptome Analyses in Gastrointestinal Malignancie NCT05462314 | Viome | — |
| Terminated | Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With NCT04566133 | National Cancer Institute (NCI) | Phase 2 |
| Withdrawn | Neoadjuvant Therapy in Biliary Adenocarcinoma NCT04480190 | Jordan Kharofa | Phase 1 |
| Active Not Recruiting | Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Mal NCT04644068 | AstraZeneca | Phase 1 / Phase 2 |
| Terminated | Quality of Life of Patients Over 75 Yars Undergoing Palliative Chemotherapy NCT04517448 | Centre Hospitalier de la côte Basque | — |
| Terminated | A Study of AbGn-107 in Patients With Gastric, Colorectal, Pancreatic or Biliary Cancer NCT02908451 | AbGenomics B.V Taiwan Branch | Phase 1 |
| Completed | Pembrolizumab and GM-CSF in Biliary Cancer NCT02703714 | Robin Kate Kelley | Phase 2 |
| Active Not Recruiting | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) NCT02628067 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | Covered Versus Uncovered SEMS for Palliation of Malignant Biliary Strictures. NCT02930252 | Azienda USL 1 Imperiese | N/A |
| Completed | My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentri NCT02091141 | Genentech, Inc. | Phase 2 |
| Completed | Preoperative Nutritional Support in Malnutritional Cancer Patients NCT02626195 | National Cancer Center, Korea | N/A |
| Completed | Tremelimumab With Chemoembolization or Ablation for Liver Cancer NCT01853618 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Postoperative Oral Nutritional Supplementation After Major Gastrointestinal Surgery NCT01838109 | Seoul National University Hospital | N/A |
| Terminated | Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer NCT01773785 | Spectrum Pharmaceuticals, Inc | Phase 2 |
| Unknown | GAMBIT Trial: Cisplatin Plus Irinotecan in the Treatment of Gallbladder or Biliary Tract Cancer NCT01859728 | Hospital de Cancer de Barretos - Fundacao Pio XII | Phase 2 |
| Completed | A Trial of Gemcitabine, Infusional 5-Fluorouracil and Cisplatin for Advanced Pancreatic and Biliary Cancers NCT01661114 | University of Michigan Rogel Cancer Center | Phase 2 |
| Completed | Perception Prognosis, Goals of Treatment, and Communication NCT01401894 | Massachusetts General Hospital | — |
| Completed | IL-2 Expressing, Attenuated Salmonella Typhimurium in Unresectable Hepatic Spread NCT01099631 | Masonic Cancer Center, University of Minnesota | Phase 1 |
| Completed | A Study of Patients Receiving High-Dose Rate Brachytherapy NCT00924027 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Study of Gemcitabine, Irinotecan and Panitumumab in Patients With Advanced and Metastatic Biliary Tract Adenoc NCT00948935 | Abramson Cancer Center at Penn Medicine | Phase 2 |
| Completed | Gemcitabine and Capecitabine to Treat Patients With Advanced Pancreatic and Biliary Cancers NCT00626158 | University of California, San Francisco | Phase 1 |
| Completed | Gemcitabine/Capecitabine/ZD6474 in Advanced Solid Tumors NCT00551096 | University of Colorado, Denver | Phase 1 |
| Terminated | GTX Regimen for Biliary Cancers NCT00868998 | Columbia University | Phase 2 |